|
Module home
Module introduction
Pre-module test
Module information
About the authors
Section 1:
Aims, policies and training issues
(1.1) Section 1: Aims, policies and training
issues
(1.2) The approach to managing acute
violence
(1.3) Study outcomes
(1.4) National guidelines and policies in the
UK
(1.5) Training issues (Royal College of
Psychiatrists)
(1.6) Section 1: Recap
(1.7) Section
1: Summary
Section 2:
Step-by-step approach to RT
(2.1) Section 2: Step-by-step approach to
RT
(2.2) Assess the situation using an MDT
approach (step 1)
(2.3) Responsibilities of the nursing team
(2.4) Responsibilities of the doctor
(2.5) Restraint (step 2)
(2.6) Reflection – clinical scenario
(2.7) Reflection – model answer
((2.8) Section 2: Recap
(2.9) Section
2: Summary
Section 3:
Determining choice of medication (step 3)
(3.1.1) Section 3: Determining choice of
medication (step 3)
(3.1.2) Section 3 Part 1: Benzodiazepines
(3.1.3) Lorazepam
(3.1.4) Studies on lorazepam
(3.1.5) Midazolam
(3.1.6) Studies on midazolam
(3.1.7) Studies on midazolam
(3.1.8) Diazepam
(3.1.9) Section 3 Part 1: Recap 1
(3.1.10) General comments on benzodiazepines
and other sedative-hypnotics
(3.1.11) General comments on benzodiazepines
and other sedative-hypnotics
(3.1.12) Flumazenil
(3.1.13) Reflection – clinical scenario
(3.1.14) Reflection – model answer
(3.1.15) Section 3 Part 1: Recap 2
(3.1.16)
Section 3 Part 1: Summary
Section 3 Part
2: First generation antipsychotics
(3.2.1) Section 3 Part 2: First generation
antipsychotics
(3.2.2) First generation antipsychotics
(3.2.3) Haloperidol
(3.2.4) Haloperidol
(3.2.5) Chlorpromazine and other conventional
antipsychotics
(3.2.6) Zuclopenthixol acetate
(3.2.7) Treatment of akathisia
(3.2.8) Reflection – clinical scenario
(3.2.9) Reflection – model answer
(3.2.10) Section 3 Part 2: Recap
(3.2.11)
Section 3 Part 2: Summary
Section 3 Part
3: Second generation antipsychotics
(3.3.1) Section 3 Part 3: Second generation
antipsychotics
(3.3.2) Olanzapine
(3.3.3) Olanzapine
(3.3.4) Risperidone and quetiapine
(3.3.5) Aripiprazole
(3.3.6) Aripiprazole: findings
(3.3.7) Section 3 Part 3: Recap
(3.3.8) Section
3 Part 3: Summary
Section 3 Part
4: Combination medicines
(3.4.1) Section 3 Part 4: Combination
medicines
(3.4.2) Combination medicines
(3.4.3) Haloperidol and lorazepam
(3.4.4) Haloperidol and lorazepam
(3.4.5) Haloperidol and promethazine
(3.4.6) Haloperidol and promethazine
(3.4.7) Other combinations
(3.4.8) Section 3 Part 4: Recap
(3.4.9) Section
3 Part 4: Summary
Section 4:
Determining route of administration (step 4)
(4.1) Section 4: Determining route of
administration (step 4)
(4.2) Oral route
(4.3) Parenteral route
(4.4) Reflection
(4.5) Reflection: model answer
(4.6) Reflection: model answer
(4.7) Reflection: model answer
(4.8) Section 4: Recap
(4.9) Section
4: Summary
Section 5:
Monitoring after RT (step 5)
(5.1) Section 5: Monitoring after RT (step
5)
(5.2) Frequency of monitoring
(5.3) Monitoring advice
(5.4) QTc interval
(5.5) QT prolongation
(5.6) QT prolongation
(5.7) Section 5: Recap 1
(5.8) Pulse oximetry
(5.9) Pulse oximetry
(5.10) Section 5: Recap 2
(5.11) Section
5: Summary
Section 6: RT
in special circumstances
(6.1) Section 6: RT in special
circumstances
(6.2) Giving RT in A&E
(6.3) RT in medical or surgical wards
(6.4) RT in medical or surgical wards
(6.5) RT and seclusion
(6.6) RT in learning disabled patients
(6.7) RT in children and adolescents
(6.8) Consent in children and adolescents
(6.9) RT in elderly patients
(6.10) High dose medications
(6.11) PRN or 'as required'
medication
(6.12) PRN or 'as required' medication
(6.13) PRNs prescribed upon admission to
hospital
(6.14) PRNs for general use
(6.15) PRNs for general use
(6.16) Section 6: Recap
(6.17) Section
6: Summary
Section 7: Risk
associated with RT and care after RT
(7.1) Section 7: Risk associated with RT and
care after RT
(7.2) Risk of harm during RT
(7.3) Risk of harm during RT
(7.4) Risks associated with
benzodiazepines
(7.5) Risks associated with antipsychotics
(7.6) Minimisation of risk
(7.7) Circumstances for special care
(7.8) Care after RT
(7.9) Care after RT
(7.10) Legal considerations
(7.11) Legal considerations
(7.12) Section 7: Recap
(7.13) Section
7: Summary
Module summary
Module test
Useful websites
References
Further reading
Useful websites
Take-home notes
Send feedback
Annual
revisions
Annual revisions
|